We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...